Drug therapy, LVAD helps severe heart failure patients recover function
American Heart Association Meeting Report – Poster: S4026 – Session: HF.APS.P11
- Advanced heart failure patients who are treated with an artificial heart assist device combined with intensive drug therapy may recover their heart function.
This news release is featured in an 8 a.m. CT news conference on Sunday, Nov. 13.
Embargoed until 8 a.m. CT/ 9 a.m. ET, Sunday, Nov. 13, 2016
NEW ORLEANS, Nov. 13, 2016 — More than a third of advanced heart failure patients treated with a combination of an artificial heart assist device, called a left ventricular assist device, or LVAD, and intensive drug therapy have recovered their heart function enough to allow removal of the LVAD device, according to preliminary results of an ongoing study presented at the American Heart Association’s Scientific Sessions 2016.
The multicenter trial called RESTAGE, includes 40 patients (67.5 percent men, average age 34.9 years) at six different centers, with very advanced or end stage heart failure. Within the first 209 days, three patients did not survive long enough to get the therapy and one had the device removed. The remaining 36 patients were implanted with an LVAD (HeartMate II) and prescribed an aggressive combination of drugs (Lisinopril 40 mg, spironolactone 25 mg, digoxin 125 mic and losartan 150 mg daily and coreg 25 mg bid).
All of the patients were so disabled from heart failure that the initial intent with the LVAD was to use it until they could receive a heart transplant or to leave the device in for the rest of their lives.
“This suggests that even very advanced heart failure can be reversed using these heart pumps, particularly when combined with additional drug therapy, avoiding the need for heart transplantation for these patients and making the donor heart available for another needy individual,” said Emma J. Birks, M.D., lead author of the study and professor of medicine at the University of Louisville in Louisville, Kentucky.
Researchers tested the 36 patients’ heart function to determine if any had improved heart function enough from the therapy to have the pumps removed, or if their heart function remained poor and needed a heart transplant or to remain on the pump.
Researcher’s preliminary results have found to date:
13 patients receiving the combination therapy had recovered enough heart function (after an average of 344 days) to have the pump removed.
Two patients received transplants from the pump and one died on the pump.
20 patients are ongoing (2 of which are also scheduled to have their devices removed).
“The fact that this could be done in several centers suggests that using the device with this drug combination to reverse heart failure is possible on a larger scale. It has previously been thought that these devices rarely recover heart function enough to allow them to be removed, but this study suggests that this can occur in a much bigger number than originally thought, particularly if combined with drug therapy,” Birks said.
Co-authors are Eduardo Rame, M.D.; Snehal R Patel, M.D.; Craig Selzman, M.D.; Chris Cunningham, Ph.D.; Randall Starling, M.D., M.P.H.; John Um, M.D.; Daniel Goldstein, M.D.; Mark Slaughter, M.D.; Pavan Alturi, M.D.; Daniel Spevack, M.D.; David Farrar, Ph.D.; Brian D. Lowes, M.D.; and Stavros G. Drakos, M.D., Ph.D. Author disclosures are on the abstract.
This study is funded by St Jude Medical.
Note: Actual scientific presentation time is 2 p.m. CT, Sunday, Nov.13, 2016 in the Science and Technology Hall, Clinical Science Section.
- AHA expert perspective video (via Skype) interview clips (for download/edit), animation and images related to this news release are on the right column of the release link at http://newsroom.heart.org/news/Xdrug-therapy-lvad-helps-severe-heart-failure-patients-recover-function?preview=519709da261e1f649588871a1e47a679
- Video clips with researchers/authors of the studies will be added to the release link after embargo.
- Rise Above Heart Failure
- For more news at AHA Scientific Sessions 2016, follow us on Twitter @HeartNews #AHA16.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
For Media Inquiries and AHA Spokesperson Perspective:
AHA News Media in Dallas: (214) 706-1173
AHA News Media Office, Nov. 12-16, 2016
at the Ernest N. Morial Convention Center: (504) 670-5106
For Public Inquiries: (800) AHA-USA1 (242-8721)
Life is why, science is how . . . we help people live longer, healthier lives.